Sandoz Group AG (XSWX:SDZ) Other Long-Term Liabilities: CHF352 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SDZ Sandoz Group AG XSWX:SDZ
11 GF Score
Price CHF65.76
! 3 Warning Signs
View Full Analysis

What is Sandoz Group AG Other Long-Term Liabilities?

Sandoz Group AG XSWX:SDZ -2.38% 11 Other Long-Term Liabilities is CHF352 Mil as of Dec. 2025. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Sandoz Group AG's other long-term liabilities for the quarter that ended in Dec. 2025 was CHF352 Mil.

Sandoz Group AG's quarterly other long-term liabilities increased from Dec. 2024 (CHF446 Mil) to Jun. 2025 (CHF662 Mil) but then declined from Jun. 2025 (CHF662 Mil) to Dec. 2025 (CHF352 Mil).

Sandoz Group AG's annual other long-term liabilities declined from Dec. 2023 (CHF509 Mil) to Dec. 2024 (CHF446 Mil) and declined from Dec. 2024 (CHF446 Mil) to Dec. 2025 (CHF352 Mil).

Sandoz Group AG Other Long-Term Liabilities Related Terms

Sandoz Group AG Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Other Long-Term Liabilities Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
491.89 508.50 445.80 352.23

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial 508.50 739.17 445.80 661.95 352.23
XSWX:SDZ
11GF Score
Sandoz Group AG XSWX:SDZ
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of CHF352 Mil mean?
Sandoz Group AG (XSWX:SDZ) has a Other Long-Term Liabilities of CHF352 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Other Long-Term Liabilities too high?
Sandoz Group AG's current Other Long-Term Liabilities is CHF352 Mil. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Other Long-Term Liabilities compare to ZTS and UTHR?
Sandoz Group AG's Other Long-Term Liabilities of CHF352 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Other Long-Term Liabilities is CHF352 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Other Long-Term Liabilities of CHF352 Mil. The current Other Long-Term Liabilities is CHF352 Mil. Sandoz Group AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Other Long-Term Liabilities is CHF352 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score

Get the complete analysis for XSWX:SDZ

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF65.76
Price